Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced on October 26, that its securityholders approved a statutory arrangement with PF Argentum ULC a wholly-owned, indirect subsidiary of Pfizer Inc. at the special meeting of Trillium securityholders. Pursuant to the arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium, other than Trillium securities owned by Pfizer and its affiliates.